市場調査レポート

商品コード

1510371

吸収不良症候群の市場規模、シェア、成長分析：原因疾患別、診断ツール別、治療法別、エンドユーザー別、地域別 - 産業予測、2024-2031年

Malabsorption Syndrome Market Size, Share, Growth Analysis, By Causative Diseases, By Diagnostic Tools(Imaging, Blood Tests ), By Treatment Modalities(Medications, Nutritional Supplements ), By End-User, By Region - Industry Forecast 2024-2031

出版日: 2024年07月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

吸収不良症候群の市場規模は、2022年に22億9,000万米ドルと評価され、2023年の24億3,000万米ドルから2031年には39億4,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは6.2％で成長する見通しです。

吸収不良症候群には、セリアック病、クローン病、その他の胃腸障害などの要因に起因する、消化管での栄養吸収障害を特徴とするさまざまな疾患が含まれます。吸収不良症候群の世界市場は、ライフスタイルの変化、食生活、高齢化により有病率が増加しており、診断ツールや治療オプションに対する需要を牽引しています。画像診断の改善、バイオマーカーの同定、遺伝子検査などの診断技術の進歩により、吸収不良症候群診断のスピードと精度が大幅に向上し、タイムリーな医療介入が可能になりました。さらに、患者や医療プロバイダーの意識が高まったことで、早期発見・早期管理が容易になった。教育の取り組みや情報の普及は、症状を認識し適切な医療を受ける力を与え、転帰の改善につながりました。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

AbbVie Inc.（United States）
Allergan plc（Ireland）
Bausch Health Companies Inc.（Canada）
Bayer AG（Germany）
Dr. Reddy's Laboratories Ltd.（India）
GlaxoSmithKline plc（United Kingdom）
Johnson & Johnson（United States）
Merck & Co., Inc.（United States）
Mylan N.V.（Netherlands）
Novartis AG（Switzerland）
Pfizer Inc.（United States）
Roche Holding AG（Switzerland）
Sanofi S.A.（France）
Takeda Pharmaceutical Company Limited（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
AstraZeneca PLC（United Kingdom）
Eisai Co., Ltd.（Japan）
Ferring Pharmaceuticals（Switzerland）
Mallinckrodt Pharmaceuticals（United Kingdom）
UCB S.A.（Belgium）

Product Code: SQMIG35D2205

Malabsorption Syndrome Market size was valued at USD 2.29 billion in 2022 and is poised to grow from USD 2.43 billion in 2023 to USD 3.94 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2024-2031).

Malabsorption Syndrome encompasses a range of conditions characterized by impaired nutrient absorption in the gastrointestinal tract, stemming from factors like celiac disease, Crohn's disease, and other gastrointestinal disorders. The global market for Malabsorption Syndrome has seen increased prevalence due to lifestyle changes, dietary habits, and an aging population, driving demand for diagnostic tools and treatment options. Advances in diagnostic technologies, including improved imaging modalities, biomarker identification, and genetic testing, have significantly enhanced the speed and accuracy of Malabsorption Syndrome diagnosis, enabling timely medical interventions. Moreover, heightened awareness among patients and healthcare providers has facilitated early detection and management. Education initiatives and information dissemination have empowered individuals to recognize symptoms and seek appropriate medical care, resulting in improved outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segmental Analysis

The global Malabsorption Syndrome market is segmented based on Causative Diseases, Diagnostic Tools, Treatment Modalities, End-User, and region. Based on Causative Diseases, the market is segmented into Celiac Disease, Crohn's Ailment, Intestinal Disorders, Whipple's Disease, Short Bowel Syndrome, and Others. Based on Diagnostic Tools, the market is segmented into Imaging (MRI, CT scans), Blood Tests (Serum nutrient levels, Genetic testing), Endoscopy & Biopsy. By treatment modalities, the market is segmented into Medications (Enzyme replacement, Anti-inflammatory drugs), Nutritional Supplements (Vitamins, Minerals), Diet Modification, Surgical Interventions. By End-User type, the market is segmented into Hospital Pharmacy, Nutrition Clinics, Academic & Research Institutes, others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Drivers of the Malabsorption Syndrome Market

Increasing incidence of malabsorption disorders, driven by factors such as evolving lifestyles, dietary patterns, and an aging population, has significantly increased the need for diagnostic and treatment solutions. Advances in diagnostic technology and heightened awareness among healthcare providers and patients have enabled early detection and intervention, positively influencing market growth.

Restraints in the Malabsorption Syndrome Market

One of the primary challenges in the market is the intricate and varied nature of malabsorption disorders, which presents difficulties in accurate diagnosis and tailored treatment. Economic factors, reimbursement challenges, and disparities in healthcare infrastructure across different regions can create obstacles to optimal patient care. Moreover, the high costs associated with advanced diagnostic technologies and specialized treatments may limit accessibility for certain populations, thereby impeding widespread adoption.

Market Trends of the Malabsorption Syndrome Market

There is an increasing focus on personalized medicine, emphasizing the customization of diagnostic and treatment approaches according to individual patient characteristics. This trend aligns with advancements in genetic testing and biomarker identification, enabling more precise and targeted interventions. Additionally, there is a notable movement towards the development of innovative therapeutic approaches, including biologics and gene therapies, demonstrating a continuous commitment to addressing the various causes of malabsorption disorders.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Malabsorption Syndrome Market Insights

Ecosystem of the Market
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Malabsorption Syndrome Market by Causative Diseases

Market Overview
Celiac Disease
Intestinal Disorders
Whipple's Disease
Short Bowel Syndrome
Others

Malabsorption Syndrome Market by Diagnostic Tools

Market Overview
Imaging
- MRI
- CT scans
Blood Tests
- Serum nutrient levels
- Genetic testing
Endoscopy
Biopsy

Malabsorption Syndrome Market by Treatment Modalities

Market Overview
Medications
- Enzyme replacement
- Anti-inflammatory drugs
Nutritional Supplements
- Vitamins
- Minerals
Diet Modification
Surgical Interventions

Malabsorption Syndrome Market by End-User

Market Overview
Hospital Pharmacy
Nutrition Clinics
Academic & Research Institutes
Others

Malabsorption Syndrome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

吸収不良症候群の市場規模、シェア、成長分析：原因疾患別、診断ツール別、治療法別、エンドユーザー別、地域別 - 産業予測、2024-2031年

Malabsorption Syndrome Market Size, Share, Growth Analysis, By Causative Diseases, By Diagnostic Tools(Imaging, Blood Tests ), By Treatment Modalities(Medications, Nutritional Supplements ), By End-User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

吸収不良症候群市場洞察

吸収不良症候群市場：原因疾患別

吸収不良症候群市場：診断ツール別

吸収不良症候群市場：治療法別

吸収不良症候群市場：エンドユーザー別

吸収不良症候群市場：地域別